NCT03514017 2026-03-02Ibrutinib and PD-1 Blockade in High Risk Lymphocytic LeukemiaH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated5 enrolled 11 charts
NCT03159702 2026-01-27Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical TransplantationMedical College of WisconsinPhase 2 Completed43 enrolled 9 charts
NCT05228470 2026-01-06A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.PfizerPhase 2 Completed39 enrolled 15 charts
NCT03578367 2025-11-10Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)NovartisPhase 2 Completed104 enrolled 11 charts
NCT01909934 2025-09-19Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaTakedaPhase 4 Completed50 enrolled 22 charts
NCT04666038 2025-04-20BRUIN CLL-321Eli Lilly and CompanyPhase 3 Active not recruiting238 enrolled 17 charts 1 FDA